PEN
$338.00
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally.
Recent News
Is Penumbra (PEN) a Solid Growth Stock? 3 Reasons to Think "Yes"
Penumbra (PEN) could produce exceptional returns because of its solid growth attributes.
What Makes Penumbra (PEN) a Good Investment Choice?
Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Small Cap Fund”. A copy of the letter can be downloaded here. The Fund seeks to invest in companies that possess franchise characteristics, with strong earnings trajectories, and are trading at a discount to the estimated private market value. Despite strong results […]
Assessing Boston Scientific (BSX) Valuation After Recent Penumbra Acquisition And Share Price Weakness
Why Boston Scientific is on investors’ radar today Boston Scientific (BSX) sits at the center of the medical devices story, and its stock performance over the past year gives investors a clear snapshot of how the market currently values that position. See our latest analysis for Boston Scientific. At a share price of US$69.13, Boston Scientific’s recent move includes a 1-day share price return of 0.85% and a 90-day share price return decline of 25.33%, while the 5-year total shareholder...
Is It Too Late To Consider Penumbra (PEN) After Strong Multi‑Year Share Price Gains?
If you are wondering whether Penumbra's current share price lines up with its underlying value, this article is designed to help you make sense of that question using clear valuation checks. Penumbra closed at US$336.18, with returns of 23.3% over 1 year, 27.8% over 3 years and 26.0% over 5 years. The shorter term picture shows a 0.7% decline over 7 days, a 0.6% decline over 30 days and an 8.6% gain year to date. These recent price moves sit against a backdrop of ongoing attention on medical...
1 Growth Stock to Stash and 2 We Avoid
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.